Whole Blood at the Front Door

For every minute you delay getting blood, plasma, or tranexamic acid into a hemorrhaging trauma patient, the adjusted odds of dying at 30 days go up 2%. That figure comes from a combined analysis of PAMPer and STAAMP, two of the most rigorous prehospital resuscitation trials ever conducted. It is not a lab model or a retrospective chart pull on a convenience sample. It is a prospective, multisite signal that says time and product are the same variable.

I ran crystalloid for over a decade. So did every flight crew I worked alongside: liter bags of normal saline, the occasional lactated Ringer's, good intentions grafted onto the wrong physiology. The shift away from that model has been building in the military trauma literature for years, and NAEMSP's April 2025 position statement is the clearest signal yet that civilian EMS medicine is committing to the same direction.

This post walks through what the paper actually argues, where the evidence is strong, where it is still catching up to practice, and why the logistics question matters as much as the clinical one.

What They Did

The NAEMSP Prehospital Trauma Compendium series is built around a structured rapid review framework using PICO questions. Brown, Yazer, Guyette, and colleagues organized the evidence into three content areas: blood components versus crystalloid, whole blood versus component therapy, and best practices for running a prehospital transfusion program. They searched PubMed and OVID for literature published between January 2000 and February 2023, screened 2,420 articles after duplicate removal, and arrived at 66 in the final review. Thirty-two addressed blood products versus crystalloid, 6 addressed whole blood versus components, and 37 addressed program logistics.

The literature base is uneven in quality and the paper is transparent about that. Formal risk-of-bias assessment and grading of evidence strength were not performed. Among the 37 articles addressing program best practices, the evidence is overwhelmingly retrospective and heterogeneous: consensus recommendations, not systematic ones. What makes the resulting guidance worth taking seriously is not that the evidence is definitive. It is that the signal runs consistently in one direction, the safety profile across thousands of cumulative prehospital transfusions is clean, and the biological case for blood over crystalloid has no credible counter-argument remaining.

Why Crystalloid Lost

Crystalloids do not carry oxygen. They do not support hemostasis. Normal saline, at scale, worsens both acidosis and coagulopathy. Those are the two mechanisms most likely to kill a hemorrhaging trauma patient before they reach the OR. This is not a recent finding. The biology was understood before most of the trial data existed. What the trials have done is confirm the clinical consequence.

The PAMPer cluster-randomized trial found that patients who received prehospital plasma had improved 30-day survival over usual care (23.2% versus 33.0% mortality, p=0.03). The RePHILL trial did not meet its primary endpoint but showed a 6% absolute and 25% relative risk reduction in 3-hour mortality, which the paper correctly identifies as the more relevant time point when studying prehospital interventions. The COMBAT trial found no significant difference in 28-day mortality, but its median transport times were 16 to 19 minutes versus PAMPer's 40 to 42 minutes. A post-hoc analysis combining both trials found the break point: when transport exceeded 20 minutes, plasma conferred a clear survival advantage.

Why Whole Blood, Not Components

The recommendation for low titer group O whole blood as the first-choice prehospital product rests on three converging arguments: biology, logistics, and safety. In the field, none of them is weak.

LTOWB provides red blood cells, plasma, and platelets in a balanced ratio: a single bag that approximates what the patient is losing. The 1:1:1 component ratio from the PROPPR trial is the in-hospital standard for balanced resuscitation, but that ratio is not achievable prehospital. You are not carrying packed cells, thawed plasma, and room-temperature platelets in a helicopter or a ground unit simultaneously. LTOWB is the only product that gets close to that physiological target in a field environment.

The platelet component is more important than it initially appears. LTOWB contains cold-stored platelets, which show higher in vitro hemostatic function than the room-temperature stored platelets used in standard component therapy. One study in the review makes this point indirectly and decisively: a leukoreduction filter that removed nearly all platelets from LTOWB showed no association with improved survival. Strip the platelets, lose the benefit. They are not incidental to the product.

LTOWB is also logistically simpler. It is universally ABO-compatible, it reduces time to effective resuscitation, and it concentrates the intervention into one product type rather than multiple components with different storage requirements and expiration windows. Cognitive load on the crew goes down at the moment when cognitive load most needs to go down. Additional potential advantages include higher hemoglobin, platelet count, and coagulation factor concentrations due to reduced anticoagulant and additive solution, as well as lower risk of fatal ABO-incompatible hemolytic reactions.

What the Retrospective Data Shows

Prehospital LTOWB is associated with improved survival to hospital arrival, improved overall 6-hour survival on adjusted analyses, and reduced in-patient transfusion requirement. One analysis found that a larger proportion of LTOWB relative to total blood transfused is associated with increased survival, further supporting the hypothesis that LTOWB is preferable to component therapy rather than merely equivalent. The association between LTOWB and survival is strengthened specifically in patients with an elevated probability of mortality. No studies have reported increased adverse events with prehospital LTOWB.

Getting the Trigger Right

The paper's third recommendation tracks closely with how experienced field clinicians already think: use a composite of indications rather than any single criterion. There is no single parameter that reliably identifies a patient who needs blood. There is a picture.

Nearly all published transfusion protocols include a systolic blood pressure threshold, most at less than 90 mmHg. Heart rate thresholds require tachycardia with additional criteria present to trigger transfusion. Shock index criteria range from 0.9 to 1.3. The paper documents the range across the literature and notes that no single criterion is robustly supported in isolation. What does appear consistently: significant hypotension, hypotension with tachycardia, and tourniquet application are each associated with trauma-induced coagulopathy, massive transfusion requirement, or need for ongoing blood product transfusion at the trauma center.

Peripheral oxygen saturation below 90% was evaluated primarily in military settings and the evidence for it in civilian contexts is weak. One report found it was not predictive of the need for prehospital transfusion, and only one study found it useful as part of a scoring system, where it was assigned the lowest point value. Point-of-care lactate above 4 mmol/L is a stronger signal where testing is available. The suggested indications table from the paper is a reasonable clinical anchor:

No single criterion here mandates transfusion in isolation. A patient with a penetrating abdominal injury and a shock index of 1.1 is a different clinical picture than a patient with a stab wound to the arm and a heart rate of 105. The composite is the point.

The Infrastructure Nobody Talks About

Coverage of prehospital blood programs tends to focus on clinical outcomes. The paper spends considerable space on something more fundamental: whether a program survives after it is built. That question is logistical, financial, and sometimes political before it is clinical.

Blood Recycling

Successful programs return blood products nearing expiration to a high-use hospital facility, typically the regional trauma center, for immediate use in the OR, ICU, or other transfusion needs. This is not a nice-to-have. It is a sustainability requirement. Programs that have built reliable recycling protocols achieve wastage rates of 1 to 2% annually, on par with in-hospital wastage rates at trauma centers for red blood cells and plasma. Programs that do not build this in lose product and eventually lose administrative support for the program.

Products with longer shelf lives reduce the recycling burden. Liquid plasma over thawed plasma is the paper's example. Commercially available thermal insulation transport coolers can maintain blood products at safe temperatures across a range of ambient conditions with minimal impact on product quality. This is a solved logistics problem in the programs that have done it. The barrier is usually organizational, not technical.

The EMS–Trauma Center–Blood Bank Triangle

Every successful prehospital transfusion program described in the literature has a strong, ongoing collaboration between the EMS agency and the blood supplier with buy-in from all stakeholders. The paper lays out what that relationship has to cover: product type, supply logistics, deployment model, resupply when units are transfused, recycling, temperature auditing, health equity, and ongoing training. A committed EMS medical director with direct, active involvement in program monitoring is described not as a feature of good programs but as a common thread in programs that persisted.

Getting buy-in from the blood banking organization is described as "a particularly difficult barrier in some locales." That is an honest acknowledgment. Blood banks carry their own regulatory obligations, expiration management pressures, and institutional risk calculations. Presenting them with cost and supply models from programs that have already demonstrated low wastage rates (the paper cites examples achieving 1–2% annual waste) is one practical pathway through that conversation.

Dispatch and Health Equity

Blood-carrying units cannot be dispatched to every trauma call. The paper raises a point that does not get enough attention: dispatch protocol needs to identify likely high-acuity hemorrhage cases before the unit arrives on scene. If that evaluation is not built into the dispatch system, the blood-carrying unit either runs to everything (unsustainable) or arrives after the window has closed. Working with national dispatch standard-setting organizations to build reliable protocol-based coding for cases most likely to need blood-carrying response is part of what program success at scale requires.

The paper also names health equity directly. A prehospital transfusion program that serves only well-resourced urban systems has not solved the access problem. It has moved it. Communities with more disadvantaged socioeconomic circumstances need the same access to prehospital transfusion when indicated. Building equity into program design from the beginning is harder than retrofitting it later.

The Continuum

Prehospital transfusion is not a standalone intervention. The paper is built around the clinical question of whether blood in the field changes outcomes, and the evidence says it does. But it only does within a system designed to receive it.

What you give in the field sets the trajectory for what follows. LTOWB starts the coagulation support. The ED continues it with a massive transfusion protocol already running. The OR surgeon operates on a patient whose clotting factors have not yet been diluted by two liters of saline. The ICU team manages a patient who arrived with less acidosis than they would have otherwise. The handoff is not a reset. It is a relay.

This matters for how programs get built and how protocols get written. A prehospital transfusion protocol that exists in isolation from the receiving trauma system is one that will miss handoff failures: product type not communicated, volume not documented, transfusion trigger criteria not passed to the ED team. The collaboration the paper recommends between EMS agencies, trauma centers, and blood suppliers is not bureaucratic process for its own sake. It is the connective tissue of a system that is supposed to work continuously across geography and time.

The resuscitation does not start when the patient arrives at the trauma bay. It starts when the call comes in. NAEMSP's position statement draws that line, clearly and with enough supporting evidence to act on. The rest is implementation.

The Critical Vector is an educational blog written by R. E. Suscitate, a medical student. Posts represent synthesis of published literature and personal clinical perspective. Nothing here constitutes clinical guidance or supersedes institutional protocol or medical direction. Apply evidence within the context of your specific system and patient.